Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098806 | 0.91 | CHRM3 (0.41) | EPHX1CD274FFAR1PDCD1TACR1 | |
| SCHEMBL12053405 | 0.90 | EPHX1 (0.44) | EPHX1CD274PDCD1 | |
| SCHEMBL4088107 | 0.89 | PDCD1 (0.41) | EPHX1CD274FFAR1PDCD1TACR1 | |
| SCHEMBL3424220 | 0.84 | CD274 (0.35) | EPHX1CD274FFAR1PDCD1 | |
| SCHEMBL3398564 | 0.84 | CHRM3 (0.41) | FFAR1TACR1 | |
| SCHEMBL1362144 | 0.82 | CD274 (0.41) | EPHX1CD274FFAR1PDCD1 | |
| SCHEMBL12053383 | 0.81 | BRD4 (0.43) | EPHX1TACR1 | |
| SCHEMBL4103863 | 0.81 | TACR1 (0.44) | FFAR1TACR1 | |
| SCHEMBL4095280 | 0.79 | TACR1 (0.44) | FFAR1TACR1 | |
| SCHEMBL3399261 | 0.78 | BRD4 (0.43) | EPHX1CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084449-B2 | Dual pharmacophores—PDE4-muscarinic antagonistics | GLAXO GROUP LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203657-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4A, PDE1A, PDE4B | EPHX1 750/4885CD274 3354/4885FFAR1 532/4885 |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | EPHX1 537/4885CD274 1066/4885FFAR1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.